Abstract Recent advancements in nanotechnology have significantly improved cancer therapy by enabling the targeted delivery of therapeutic agents directly to cancerous tissues, thereby reducing systemic toxicity. Among these advancements, liposomes—lipid-based vesicles—have shown promise as versatile platforms for delivering enzymes and cofactors necessary for DNA demethylation. This critical process reverses oncogenic characteristics in cancer cells by reactivating silenced tumor suppressor genes. This paper investigates the application of liposomal nanotechnology in DNA demethylation therapies, focusing on their role in enhancing drug delivery precision and therapeutic efficacy. Surface modifications with targeting ligands improve liposomal specificity, while design advancements enhance stability and functionality within complex biological environments. Additionally, liposomes offer unique advantages such as triggered release mechanisms that respond to tumor microenvironment cues and the co-delivery of multiple agents for synergistic effects. By highlighting these capabilities, this research contributes to the development of tailored cancer therapies aimed at improving treatment outcomes and minimizing adverse effects.